National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (1)
- Asthma (2)
- Behavioral Health (1)
- Cancer (2)
- Cancer: Colorectal Cancer (1)
- Cardiovascular Conditions (2)
- Caregiving (1)
- Care Management (2)
- Children/Adolescents (6)
- (-) Chronic Conditions (40)
- Diabetes (4)
- Elderly (3)
- Emergency Department (1)
- Family Health and History (1)
- Guidelines (2)
- Healthcare Cost and Utilization Project (HCUP) (4)
- (-) Healthcare Costs (40)
- Healthcare Delivery (3)
- Healthcare Utilization (7)
- Health Insurance (2)
- Health Services Research (HSR) (1)
- Heart Disease and Health (1)
- Hospitalization (3)
- Kidney Disease and Health (3)
- Low-Income (3)
- Medicaid (2)
- Medical Expenditure Panel Survey (MEPS) (7)
- Medicare (2)
- Medication (9)
- Mortality (1)
- Neurological Disorders (2)
- Obesity (1)
- Palliative Care (1)
- Patient-Centered Healthcare (1)
- Patient-Centered Outcomes Research (1)
- Patient Adherence/Compliance (2)
- Patient Self-Management (1)
- Primary Care (1)
- Quality of Care (1)
- Quality of Life (2)
- Respiratory Conditions (6)
- Screening (1)
- Shared Decision Making (1)
- Surgery (1)
- Teams (1)
- Treatments (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 25 of 40 Research Studies DisplayedCusick MM, Tisdale RL, Chertow GM
Population-wide screening for chronic kidney disease : a cost-effectiveness analysis.
The purpose of this study was to assess the cost-effectiveness of adding population-wide screening for chronic kidney disease (CKD), specifically; screening for albuminuria with and without adding Sodium-glucose cotransporter-2 (SGLT2) inhibitors to the current standard of care for CKD. The study found that one-time CKD screening at the age 55 years had an ICER of $86,300 per QALY gained by increasing costs from $249,800 to $259,000 and increasing QALYs from 12.61 to 12.72; this result was accompanied by a decrease in the incidence of kidney failure requiring dialysis or kidney transplant of 0.29 percentage points and an increase in life expectancy from 17.29 to 17.45 years. In the group aged 35 to 75 years, screening one time prevented dialysis or transplant in 398, 000 people and screening every 10 years until age the age of 75 years cost less than $100,000 per QALY gained. The study’s sensitivity analysis found that when SGLT2 inhibitors were 30% less effective, screening every 10 years during ages 35 to 75 years cost between $145,400 and $182,600 per QALY gained, and decreases in the price would be necessary for screening to be cost-effective.
AHRQ-funded; HS026128.
Citation: Cusick MM, Tisdale RL, Chertow GM .
Population-wide screening for chronic kidney disease : a cost-effectiveness analysis.
Ann Intern Med 2023 Jun; 176(6):788-97. doi: 10.7326/m22-3228..
Keywords: Kidney Disease and Health, Screening, Healthcare Costs, Chronic Conditions
Dunbar PJ, Sobotka SA, Rodean J
Prevalence of and spending on ear, nose, throat, and respiratory infections among children with chronic complex conditions.
The impact of ear, nose, throat, and respiratory infections (ENTRIs) on children with complex chronic conditions (CCCs) may vary from that of their counterparts. The purpose of this study was to examine the prevalence and expenditure of ENTRIs in children with and without CCCs. A retrospective evaluation of 3,880,456 children aged 0-18 years enrolled in 9 US state Medicaid programs in 2018, as recorded in the IBM Watson Marketscan Database, was conducted. Feudtner's classification system was employed to identify the type and quantity of CCCs. The prevalence of ENTRIs, defined as one or more healthcare visits for ENTRIs, and Medicaid expenditure on ENTRIs were compared based on CCC status using chi-square tests and logistic regression. The study found that ENTRIs were more prevalent in children with CCCs than in those without. Children with a CCC represented approximately one-fourth ($145.8 million [US]) of the total ENTRI expenditure. Excluding throat and sinus infections, the prevalence of ENTRIs rose with the number of CCCs. For instance, the prevalence of lower-airway infections increased from 12.5% to 37.5% as the number of CCCs grew from zero to ≥3. Inpatient care-associated ENTRI expenditure rose from 9.7% to 92.8% as the number of CCCs increased from zero to ≥3.
AHRQ-funded; HS025138
Citation: Dunbar PJ, Sobotka SA, Rodean J .
Prevalence of and spending on ear, nose, throat, and respiratory infections among children with chronic complex conditions.
Acad Pediatr 2023 Mar;23(2):434-40. doi: 10.1016/j.acap.2022.07.004.
Keywords: Children/Adolescents, Respiratory Conditions, Chronic Conditions, Healthcare Costs
Duan KI, Birger M, Au DH
Health care spending on respiratory diseases in the United States, 1996-2016.
The objectives of this study were to estimate health care spending in the U.S. for 11 respiratory conditions from 1996 to 2016, and to provide an evaluation of factors associated with spending growth and detailed trends. Data was taken from the Institute of Health Metrics and Evaluation's Disease Expenditure Project Database. The results showed that spending on respiratory conditions is high, particularly for chronic conditions like asthma and chronic obstructive pulmonary disease. The authors concluded that these findings suggest that service price and intensity should be a key focus for policymakers who seek to reduce health care spending growth.
AHRQ-funded; HS026369.
Citation: Duan KI, Birger M, Au DH .
Health care spending on respiratory diseases in the United States, 1996-2016.
Am J Respir Crit Care Med 2023 Jan 15; 207(2):183-92. doi: 10.1164/rccm.202202-0294OC..
Keywords: Respiratory Conditions, Healthcare Costs, Asthma, Chronic Conditions
Chang E, Ali R, Seibert J
Interventions to improve outcomes for high-need, high-cost patients: a systematic review and meta-analysis.
The authors of this article reviewed evidence on the effectiveness of complex interventions designed to change the healthcare of high-need, high-cost patients. They found limited evidence of intervention effectiveness in relation to cost and use, but note that additional evidence is needed to strengthen their confidence in these findings. Few studies reported clinical/functional or social risk factor outcomes or sufficient details for determining why individual interventions work. They conclude that future evaluations could provide additional insights in assessing the impact of complex interventions.
AHRQ-funded; 290201500011I.
Citation: Chang E, Ali R, Seibert J .
Interventions to improve outcomes for high-need, high-cost patients: a systematic review and meta-analysis.
J Gen Intern Med 2023 Jan; 38(1):185-94. doi: 10.1007/s11606-022-07809-6..
Keywords: Healthcare Costs, Healthcare Delivery, Chronic Conditions, Healthcare Utilization
Nuckols TK, Dworsky M, Conlon C
The quality of occupational healthcare for carpal tunnel syndrome, healthcare expenditures, and disability outcomes: a prospective observational study.
The authors sought to examine whether quality of care for work-associated carpal tunnel syndrome (CTS) is associated with healthcare expenditures or disability. They examined workers' compensation claims for CTS and created patient-level aggregate quality scores for underuse and overuse of care. They concluded that improved quality of care might increase or lower short-term healthcare expenditures, depending on how often care is underused or overused. Future research is needed in varied workers' compensation contexts. Quality of care was not found to be associated with disability.
AHRQ-funded; HS018982.
Citation: Nuckols TK, Dworsky M, Conlon C .
The quality of occupational healthcare for carpal tunnel syndrome, healthcare expenditures, and disability outcomes: a prospective observational study.
Muscle Nerve 2023 Jan;67(1):52-62. doi: 10.1002/mus.27718..
Keywords: Chronic Conditions, Healthcare Costs
Berkman ND, Chang E, Seibert J
Characteristics of high-need, high-cost patients : a "best-fit" framework synthesis.
This paper’s objective was to identify characteristics and criteria to distinguish high-need, high-cost (HNHC) patients. Searches of multiple databases and gray literature from 2000 to January 2022 were conducted. The final review included 64 studies comprising multivariate exposure studies (n = 47), cluster analyses (n = 11), and qualitative studies (n = 6). National Academy of Medicine (NAM) taxonomy was used for organizing the synthesis of findings. Patient characteristics associated with being defined as HNHC included number and severity of comorbid conditions and having chronic clinical conditions, particularly heart disease, chronic kidney disease, chronic lung disease, diabetes, cancer, and hypertension. HNHC risk was often amplified by behavioral health conditions and social risk factors. The authors revised the NAM taxonomy to create a final framework, adding chronic pain and prior patterns of high health care use as characteristics associated with an increased risk for being HNHC.
AHRQ-funded; 290201500011I
Citation: Berkman ND, Chang E, Seibert J .
Characteristics of high-need, high-cost patients : a "best-fit" framework synthesis.
Ann Intern Med 2022 Dec;175(12):1728-41. doi: 10.7326/m21-4562..
Keywords: Chronic Conditions, Healthcare Costs, Healthcare Delivery
Becker NV, Scott JW, Moniz MH
Association of chronic disease with patient financial outcomes among commercially insured adults.
This study examined the association between chronic disease and adverse financial outcomes. The authors used claims data for patients enrolled in a preferred provider organization in Michigan. Patients diagnosed with thirteen common chronic conditions (cancer, congestive heart failure, chronic kidney disease, dementia, depression and anxiety, diabetes, hypertension, ischemic heart disease, liver disease, chronic obstructive pulmonary disease and asthma, serious mental illness, stroke, and substance use disorders) were included in the cohort of 2,854,481 adults aged 21 and over. The cohort included 61.4% with no chronic conditions, 17.7% with 1 chronic condition, 14.8% with 2 to 3 chronic conditions, 5.4% with 4 to 6 chronic conditions, and 0.7% with 7 to 13 chronic conditions. Among the cohort, 9.6% had medical debt in collections, 8.3% had nonmedical debt in collections, 16.3% had delinquent debt, 19.3% had a low credit score, and 0.6% had recent bankruptcy. For individuals with 0 vs 7 to 13 chronic conditions, the predicted probabilities of having any medical debt in collections (7.6% vs 32%), any nonmedical debt in collections (7.2% vs 24%), any delinquent debt (14% vs 43%), a low credit score (17% vs 47%) or recent bankruptcy (0.4% vs 1.7%) were all considerably higher for individuals with more chronic conditions and increased with each added chronic condition. Among individuals with medical debt in collections, the estimated amount increased with the number of chronic conditions ($784 for individuals with 0 conditions vs $1252 for individuals with 7-13 conditions).
AHRQ-funded; HS028672.
Citation: Becker NV, Scott JW, Moniz MH .
Association of chronic disease with patient financial outcomes among commercially insured adults.
JAMA Intern Med 2022 Oct;182(10):1044-51. doi: 10.1001/jamainternmed.2022.3687..
Keywords: Chronic Conditions, Healthcare Costs, Cancer, Kidney Disease and Health
Glynn A, Hernandez I, Roberts ET
Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
This study’s objective was to estimate the take-up of the Medicare Part D Low-Income Subsidy (LIS) among Medicare beneficiaries with diabetes and examine differences in out-of-pocket costs and prescription drug use between LIS enrollees and LIS-eligible non-enrollees. Data from the Health and Retirement Study linked to Medicare administrative data from 2008 to 2016 was used. The authors first estimated LIS take-up stratified by income (≤100% of the Federal Poverty Level [FPL] and >100% to ≤150% of FPL). Second, to assess the consequences of forgoing the LIS among near-poor beneficiaries (incomes >100% to ≤150% of FPL), they conducted propensity score-weighted regression analyses to compare out-of-pocket costs, prescription drug use, and cost-related medication non-adherence among LIS enrollees and LIS-eligible non-enrollees. Among Medicare beneficiaries with diabetes, 68.1% of those considered near-poor (incomes >100% to ≤150% of FPL) received the LIS, compared to 90.3% of those with incomes ≤100% of FPL. Among near-poor beneficiaries, LIS-eligible non-enrollees incurred higher annual out-of-pocket drug spending ($518], filled 7.3 fewer prescriptions for diabetes, hypertension, and hyperlipidemia drugs, and were 8.9 percentage points more likely to report skipping drugs due to cost. all compared to LIS enrollees.
AHRQ-funded; HS026727.
Citation: Glynn A, Hernandez I, Roberts ET .
Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Health Serv Res 2022 Oct;57(5):1136-44. doi: 10.1111/1475-6773.13990..
Keywords: Medication, Diabetes, Chronic Conditions, Low-Income, Medicare, Healthcare Costs
Tisdale RL, Cusick MM, Aluri KZ
Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease.
The purpose of this study was to determine the cost-effectiveness of adding dapagliflozin to standard management of patients with non-diabetic chronic kidney disease (CKD). Findings showed that adding dapagliflozin to standard care improved life expectancy by 2 years, increased discounted quality-adjusted life years, and reduced the total incidence of both kidney failure on kidney replacement therapy (KRT) and average years on KRT over the lifetime of the cohort. Further, dapagliflozin plus standard care was more effective than standard care alone while increasing lifetime costs.
AHRQ-funded; HS026128.
Citation: Tisdale RL, Cusick MM, Aluri KZ .
Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease.
J Gen Intern Med 2022 Oct;37(13):3380-87. doi: 10.1007/s11606-021-07311-5..
Keywords: Kidney Disease and Health, Medication, Chronic Conditions, Healthcare Costs
Nguyen JT, Cole AL, Leech AA
Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia.
AHRQ-funded; HS000032.
Citation: Nguyen JT, Cole AL, Leech AA .
Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia.
Value Health 2020 Oct;23(10):1292-99. doi: 10.1016/j.jval.2020.05.019..
Keywords: Chronic Conditions, Medication, Healthcare Costs, Treatments
Iyer AS, Goodrich CA, Dransfield MT
End-of-life spending and healthcare utilization among older adults with chronic obstructive pulmonary disease.
This study examined end-of-life spending and healthcare utilization among Medicare beneficiaries aged 65 years or older with chronic obstructive pulmonary disease (COPD) who died during the period 2013-2014. Data on 146,240 decedents with COPD was investigated from 306 hospital referral regions (HRRs). The overall spending during the last 2 years of life varied significantly nationwide. Inpatient care accounted for 40.2% of spending, with 82% of decedents admitted to the hospital for 13.7±3.1 days and 55%±11% admitted to an intensive care unit for 3-7 days. Skilled nursing facilities accounted for 11.6% of spending and were utilized by 31-45% of decedents for 14-23 days. Hospitals were utilized by 39-56% of decedents and accounted for 10.3% of spending.
AHRQ-funded; HS023009.
Citation: Iyer AS, Goodrich CA, Dransfield MT .
End-of-life spending and healthcare utilization among older adults with chronic obstructive pulmonary disease.
Am J Med 2020 Jul;133(7):817-24.e1. doi: 10.1016/j.amjmed.2019.11.024..
Keywords: Elderly, Healthcare Utilization, Respiratory Conditions, Chronic Conditions, Healthcare Costs, Palliative Care
Flory JH, Mushlin AI
Effect of cost and formulation on persistence and adherence to initial metformin therapy for type 2 diabetes.
This paper studied whether persistence and adherence to initial release (IR) metformin was at the same levels as extended release (ER) metform for adults with type 2 diabetes. A study was conducted using merged de-identified claims data from commercial insurance carriers in the US from 2012 to 2016. The cohort used was identified as patients aged 18 years or older who filled an initial 30-day prescription for metformin monotherapy with a baseline type 2 diabetes diagnosis, at least 1 year of baseline and follow-up data, and no prior antidiabetes drug use. “Persistence” was defined as at least one metformin prescription claim during the 6-12 month window after the initial prescription. “Adherence” was defined as the percentage of days for which the patient had filled sufficient prescriptions to be taking it “as prescribed”. The final study population was 81,406 patients, with 78% having commercial insurance, 19% Medicare Advantage, and 2.5% were dual-eligible for Medicare and Medicare. Persistence was slightly higher for ER metformin than for IR metformin, as was adherence and adequate adherence (80% or more). Despite the slightly higher cost, initial use of ER metformin was associated with better adherence.
AHRQ-funded; HS023898.
Citation: Flory JH, Mushlin AI .
Effect of cost and formulation on persistence and adherence to initial metformin therapy for type 2 diabetes.
Diabetes Care 2020 Jun;43(6):e66-e67. doi: 10.2337/dc19-2426..
Keywords: Diabetes, Chronic Conditions, Healthcare Costs, Medication, Patient Adherence/Compliance
Mszar R, Grandhi GR, Valero-Elizondo J
Cumulative burden of financial hardship from medical bills across the spectrum of diabetes mellitus and atherosclerotic cardiovascular disease among non-elderly adults in the United States.
This study looked at the rates of financial hardship from medical bills with non-elderly adults diagnosed with diabetes mellitus (DM) and diagnosed with and without atherosclerotic cardiovascular disease (ASCVD). ASCVD with DM accounts for approximately two-thirds of deaths in this patient population. Data from the National Health Interview Survey from 2013 to 2017 was used, with a total study population of 121,672 individuals. Approximately 3.1% of the population had ASCVD, 5.6% had DM, and 1.3% had both. Almost half of individuals with both conditions reported financial hardship from medical bills, with 23% unable to pay medical bills at all, compared to around 28% of those with neither ASCVD and DM reporting financial hardship with 8% being unable to pay at all.
AHRQ-funded; HS023000.
Citation: Mszar R, Grandhi GR, Valero-Elizondo J .
Cumulative burden of financial hardship from medical bills across the spectrum of diabetes mellitus and atherosclerotic cardiovascular disease among non-elderly adults in the United States.
J Am Heart Assoc 2020 May 18;9(10):e015523. doi: 10.1161/jaha.119.015523..
Keywords: Diabetes, Cardiovascular Conditions, Chronic Conditions, Healthcare Costs
Cole AL, Wood WA, Muluneh B
Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib.
Tyrosine kinase inhibitors (TKIs) have dramatically improved survival for patients with chronic myeloid leukemia (CML). No overall survival differences were observed between patients initiating first- and second-generation TKIs in trials; however, real-world safety and cost outcomes are unclear. In this study, the investigators evaluated comparative safety and health care expenditures between first-line imatinib, dasatinib, and nilotinib among patients with CML.
AHRQ-funded; HS000032.
Citation: Cole AL, Wood WA, Muluneh B .
Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib.
JCO Oncol Pract 2020 May;16(5):e443-e55. doi: 10.1200/jop.19.00301..
Keywords: Chronic Conditions, Healthcare Costs, Medication
Shaker M, Briggs A, Dbouk A
Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab.
Biologic therapy is a paradigm-shifting management strategy for many patients with asthma and chronic urticaria, but concerns for therapy-associated anaphylaxis may limit access to these therapies for patients unable to travel to medical clinics. The objective of this study was to characterize the cost-effectiveness of in-clinic versus at-home biologic therapy with omalizumab and mepolizumab.
AHRQ-funded; HS024599.
Citation: Shaker M, Briggs A, Dbouk A .
Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab.
J Allergy Clin Immunol Pract 2020 Feb;8(2):565-72. doi: 10.1016/j.jaip.2019.09.037..
Keywords: Medication, Healthcare Costs, Asthma, Respiratory Conditions, Chronic Conditions
Cheng BT, Smith SS, Fishbein AB
Functional burden and limitations in children with chronic sinusitis.
The objective of this study was to use a validated pediatric quality of life (QOL) tool to quantify the impact of pediatric chronic rhinosinusitis (CRS) in a representative epidemiological sample. Findings showed that pediatric CRS was associated with substantial QOL burden across multiple psychosocial and cognitive domains and that CRS children with lower family income and comorbid asthma, anxiety, and depression had higher Columbia Impairment Scale scores associated with even greater functional impairment. These findings suggested that pediatric CRS might be a population requiring greater attention and screening for mental health symptoms.
AHRQ-funded; HS023011.
Citation: Cheng BT, Smith SS, Fishbein AB .
Functional burden and limitations in children with chronic sinusitis.
Pediatr Allergy Immunol 2020 Jan;31(1):103-05. doi: 10.1111/pai.13121..
Keywords: Medical Expenditure Panel Survey (MEPS), Children/Adolescents, Quality of Life, Healthcare Costs, Respiratory Conditions, Chronic Conditions
Biener AI, Decker SL, Rohde F
AHRQ Author: Decker SL, Rohde F
Prevalence and treatment of chronic obstructive pulmonary disease (COPD) in the United States.
This infographic depicts MEPS data concerning the prevalence and treatment of chronic obstructive pulmonary disease, including information on costs, medications and other chronic conditions.
AHRQ-authored.
Citation: Biener AI, Decker SL, Rohde F .
Prevalence and treatment of chronic obstructive pulmonary disease (COPD) in the United States.
JAMA 2019 Aug 20;322(7):602. doi: 10.1001/jama.2019.10241..
Keywords: Medical Expenditure Panel Survey (MEPS), Respiratory Conditions, Care Management, Chronic Conditions, Healthcare Costs
Shaker M, Greenhawt M
A primer on cost-effectiveness in the allergy clinic.
This paper examines ways to incorporate cost-effectiveness into care at allergy clinics. The article discusses in general terms how to use cost-effective analyses (CEA) to grade health outcomes and economic benefits. The authors state that future research is needed to provide a better understanding of variation across population health state utilities for allergic conditions and to more accurately reflect quality adjusted life years for patients with allergies.
AHRQ-funded; HS024599.
Citation: Shaker M, Greenhawt M .
A primer on cost-effectiveness in the allergy clinic.
Ann Allergy Asthma Immunol 2019 Aug;123(2):120-28.e1. doi: 10.1016/j.anai.2019.05.012..
Keywords: Healthcare Costs, Chronic Conditions, Healthcare Delivery
Biener AI, Decker SL, Rohde F
AHRQ Author: Deck SL, Rohde F
Source of increased health care spending in the United States.
This infographic depicts MEPS information for five medical conditions that account for nearly 1/3 of all medical expenditures in 2015. Factors include the difference in spending associated with these conditions; the number of people treated for them; per capita costs; and related ambulatory visits and prescription drug costs as a proportion of health expenditures.
AHRQ-authored.
Citation: Biener AI, Decker SL, Rohde F .
Source of increased health care spending in the United States.
JAMA 2019 Mar 26;321(12):1147. doi: 10.1001/jama.2019.0679..
Keywords: Chronic Conditions, Healthcare Costs, Healthcare Utilization, Medical Expenditure Panel Survey (MEPS)
Smith GH, Shore S, Allen LA
Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure.
This study examined how prescription costs can greatly impact decision-making in patients with serious medical conditions. Forty-nine patients with heart failure with reduced ejection fracture were recruited and interviewed about a drug sacrubitril-valsartan. The drug is considered effective but can be costly. Most patients (45/49) said they would take the medicine if the out-of-pocket cost was only $5 per month more than their current medication. But if the costs increased to $100 more per month then only 43% would switch to sacrubritil-valsartan. Only 20% of participants said their physician had discussed medication costs in the past year.
AHRQ-funded; HS026081.
Citation: Smith GH, Shore S, Allen LA .
Discussing out-of-pocket costs with patients: shared decision making for sacubitril-valsartan in heart failure.
J Am Heart Assoc 2019 Jan 8;8(1):e010635. doi: 10.1161/jaha.118.010635..
Keywords: Healthcare Costs, Shared Decision Making, Heart Disease and Health, Cardiovascular Conditions, Medication, Chronic Conditions
Meyers DJ, Chien AT, Nguyen KH
Association of team-based primary care with health care utilization and costs among chronically ill patients.
This study analyzed the value of team-based care practice on the treatment of patients, especially those with multiple chronic conditions. A large study was conducted using data from 18 academically affiliated primary care practices in the Boston, Massachusetts, area between 2011 and 2015. The study included 83,953 patients total with 19% of patients being younger than 18 years and the rest from 19-64 years of age. For patients with multiple chronic conditions, there was a statistically significant reduction in hospitalizations and emergency department visits. Among patients with less than 2 comorbidities, there was an increase in outpatient visits, hospitalizations and ambulatory care hospitalizations.
AHRQ-funded; HS000011.
Citation: Meyers DJ, Chien AT, Nguyen KH .
Association of team-based primary care with health care utilization and costs among chronically ill patients.
JAMA Intern Med 2019 Jan;179(1):54-61. doi: 10.1001/jamainternmed.2018.5118..
Keywords: Chronic Conditions, Emergency Department, Healthcare Costs, Healthcare Utilization, Primary Care, Teams
Abdus S, Keenan PS
AHRQ Author: Abdus S, Keenan PS
Financial burden of employer-sponsored high-deductible health plans for low-income adults with chronic health conditions.
In this research letter, the authors used 2011-2015 Medical Expenditure Panel Survey Household Component data on adults 19 to 64 years of age enrolled in employer-sponsored insurance plans throughout the year to examine the burden of high deductible health plans on low income adults with chronic health conditions.
AHRQ-authored.
Citation: Abdus S, Keenan PS .
Financial burden of employer-sponsored high-deductible health plans for low-income adults with chronic health conditions.
JAMA Intern Med 2018 Dec;178(12):1706-08. doi: 10.1001/jamainternmed.2018.4706..
Keywords: Chronic Conditions, Healthcare Costs, Health Insurance, Low-Income, Medical Expenditure Panel Survey (MEPS)
Bettenhausen JL, Richardson TE, Shah SS
Medicaid expenditures among children with noncomplex chronic diseases.
This study analyzed Medicaid use by children with noncomplex chronic diseases (NC-CDs). The objective was to describe patient characteristics, expenditures, and use patterns. The researchers used the 2014 Truven Medicaid MarketScan Database to analyze claims from 11 states. Mental health conditions accounted for half of the inpatient diagnosis, with the expenditures high as well. One-percent of children with the highest expenditures accounted for 20% of the total Medicaid expenditures.
AHRQ-funded; HS024735.
Citation: Bettenhausen JL, Richardson TE, Shah SS .
Medicaid expenditures among children with noncomplex chronic diseases.
Pediatrics 2018 Nov;142(5). doi: 10.1542/peds.2018-0286..
Keywords: Children/Adolescents, Chronic Conditions, Healthcare Costs, Medicaid
Silber JH, Rosenbaum PR, Wang W
Practice style variation in Medicaid and non-Medicaid children with complex chronic conditions undergoing surgery.
With differential payment between Medicaid and Non-Medicaid services, researchers asked whether style-of-practice differs between similar Medicaid and Non-Medicaid children with complex chronic conditions (CCCs) undergoing surgery. They found that treatment style differences between Medicaid and Non-Medicaid children were small, suggesting little disparity with in-hospital surgical care for patients with CCCs operated on within Children's Hospitals.
AHRQ-funded; HS020508.
Citation: Silber JH, Rosenbaum PR, Wang W .
Practice style variation in Medicaid and non-Medicaid children with complex chronic conditions undergoing surgery.
Ann Surg 2018 Feb;267(2):392-400. doi: 10.1097/sla.0000000000002061.
.
.
Keywords: Children/Adolescents, Chronic Conditions, Healthcare Costs, Medicaid, Surgery
Biener AI, Decker SL
AHRQ Author: Biener AI, Decker SL
Medical care use and expenditures associated with adult obesity in the United States.
This infographic consists of bar charts and a line graph making the following points: (1) adult obesity is associated with higher prevalence of chronic conditions, (2) growth in total medical expenditures among obese adults is outpacing that of normal weight adults, and (3) most medical expenditures rise as body mass index increases to higher than normal levels.
AHRQ-authored.
Citation: Biener AI, Decker SL .
Medical care use and expenditures associated with adult obesity in the United States.
JAMA 2018 Jan 16;319(3):218. doi: 10.1001/jama.2017.21063.
.
.
Keywords: Chronic Conditions, Healthcare Costs, Medical Expenditure Panel Survey (MEPS), Obesity